Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC - Takeaways - DentalSpire

Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC

  • By

  • Dongmei Ji

  • Wenmin Fu

  • Yonghong Liu

  • Weina Shen

  • Muyu Kuang

  • Zhouyu Ning

  • Youzhou Sang

  • Guangliang Chen

  • Jian Zhang

  • Zijie Zhou

  • Dashuang Xu

  • Xu Jin

  • Junlong Wu

  • Xusha Zhou

  • Jing Zhao

  • Lei Wang

  • Yukun Liu

  • Xi Zhang

  • Runbin Yan

  • Xiaoqing Chen

  • Grace Zhou

  • Jiaxin Niu

  • Xichun Hu

  • February 20, 2026

  • 0 min

Share

  • 1

    T3011 is an oncolytic virus designed to selectively target cancer cells while minimizing damage to normal tissues.

  • 2

    The therapy combines IL-12 and anti-PD-1 antibody to enhance anti-tumor immune responses and reduce systemic toxicity.

  • 3

    HNSCC, particularly HPV+ types, presents unique treatment challenges and has limited effective options after standard therapies.

  • 4

    The phase 1/2a trial evaluates T3011's safety and efficacy in advanced solid tumors, including recurrent or metastatic HNSCC.

  • 5

    The study employs a dose-escalation design to determine the optimal dosing and assess viral biodistribution and safety.

Original Source(s)

Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC

  • by Dongmei Ji, Wenmin Fu, Yonghong Liu, Weina Shen, Muyu Kuang, Zhouyu Ning, Youzhou Sang, Guangliang Chen, Jian Zhang, Zijie Zhou, Dashuang Xu, Xu Jin, Junlong Wu, Xusha Zhou, Jing Zhao, Lei Wang, Yukun Liu, Xi Zhang, Runbin Yan, Xiaoqing Chen, Grace Zhou, Jiaxin Niu, Xichun Hu

  • February 20, 2026

Related Content

Distress Screening in a Cancer Survivorship Clinic: Impact on Psychosocial Referrals

This quality improvement project found that using a distress screening tool for head and neck cancer patients who were 2 or more years post-treatment led to an increased number of referrals for psychosocial needs.

Tracking Opioid Refills After Surgery

Researchers evaluated perioperative and postdischarge factors associated with opioid refill prescriptions during the first 90 days after inpatient otolaryngology–head and neck surgery.

Ergonomic Risk in Head and Neck Surgery

Study suggests intraoperative pain and risk rise with case complexity and duration.